Androgen Suppression With Abiraterone, Leuprolide, PARP Inhibitor and Stereotactic Radiotherapy in Prostate Cancer (ASCLEPIuS) identifier:
NCT04194554 (

Newly diagnosed prostate cancer grade group 3-5

Study Contact Information:

For additional information, contact:
Cancer AnswerLine: 800-865-1125
or by email at:  [email protected]  

About the Study

This study will look at treating men with high risk prostate cancer using the PARP inhibitor, niraparib combined with prostate stereotactic body radiotherapy (SBRT), abiraterone, leuprolide, and prednisone. Phase 1 of this study will look at the best dose of niraparib for this treatment combination. The phase 2 portion of this study will look at the 3-year PSA recurrence free-survival rate of the patients who received this combined therapy.

What the Study Entails

This is an open label, single-group study.

All study participants will receive the following:

Study Locations

Ann Arbor, MI
University of Michigan Rogel Cancer Center    
Contact: Cancer AnswerLine: 800-865-1125
or by email at:  [email protected]  
Principal Investigator: William Jackson, MD       

New York
New York, NY
Weill Cornell Medicine
Contact: Sharanya Chandrasekhar, MS: 646-962-2196
or by email at:  [email protected]     
Contact: Pragya Yadav, PhD: 646-962-2199
or by email at: [email protected]        
Principal Investigator: Himanshu Nagar, MD      

Cleveland, OH
University Hospitals Seidman Cancer Center 
Contact: Daniel Spratt, MD:  216-293-6191      
or by email at: [email protected]
Principal Investigator: Daniel Spratt, MD        

Dallas, TX
University of Texas Southwestern   
Contact: Cancer AnswerLine at UTSW: 833-722-6237 
or by email at: [email protected]     
Principal Investigator: Neil Desai, MD, MHS           

This Study is Open To:

Men age 18 years or older who meet the following criteria:

This Study is Not Open To:

People with the following are not eligible:


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.